Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients
subject: covid-19, antiviral activity, SARS-CoV-2, p53, MDM2, idasanutlin
creator: Giorgio Zauli, Veronica Tisato, Paola Secchiero
source: Epidemiology and Health
publisher: Korean Society of Epidemiology
date: 2020
coverage: Therapeutics. Pharmacology